Actimab-A

BrainStorm Advances NurOwn ALS Program Toward Phase 3b

New York, United States, August 14, 2026 BrainStorm Cell Therapeutics Inc. announced its financial results for the second quarter...

By cGxPwire Editor
August 17, 2026

Pharma

Kyowa Kirin Advances AI-Powered Drug Discovery R&D

Tokyo, Japan, August 16, 2026 Kyowa Kirin Co., Ltd. has selected Cognizant and Benchling as partners to implement an...

By cGxPwire Editor
August 17, 2026

Bio-Pharma

Actinium Advances Actimab-A With Manufacturing Expansion

New York, United States, August 14, 2026 Actinium Pharmaceuticals, Inc. announced new intellectual property and manufacturing developments supporting its...

By cGxPwire Editor
August 17, 2026

Bio-Pharma

Actinium Strengthens IP Portfolio for Radiotherapy Programs

NEW YORK, May 29, 2026 Actinium Pharmaceuticals, Inc. has announced the receipt of two patent allowances from the Canadian...

By cGxPwire Editor
June 1, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

BrainStorm Advances NurOwn ALS Program Toward Phase 3b

Kyowa Kirin Advances AI-Powered Drug Discovery R&D

Actinium Advances Actimab-A With Manufacturing Expansion

Actinium Strengthens IP Portfolio for Radiotherapy Programs